cafergot pb sup suppository
novartis pharmaceuticals canada inc - ergotamine (ergotamine tartrate); caffeine; belladonna; pentobarbital - suppository - 2mg; 100mg; 0.25mg; 60mg - ergotamine (ergotamine tartrate) 2mg; caffeine 100mg; belladonna 0.25mg; pentobarbital 60mg - sympatholytic (adrenergic blocking) agents
pms-dihydroergotamine liquid
pharmascience inc - dihydroergotamine mesylate - liquid - 4mg - dihydroergotamine mesylate 4mg - sympatholytic (adrenergic blocking) agents
pms-dihydroergotamine liquid
pharmascience inc - dihydroergotamine mesylate - liquid - 1mg - dihydroergotamine mesylate 1mg - sympatholytic (adrenergic blocking) agents
migergot ergotamine tartrate and caffeine suppository
crealta pharmaceuticals llc - ergotamine tartrate (unii: mru5xh3b48) (ergotamine - unii:pr834q503t) - ergotamine tartrate 2 mg
ergotamine 1mg / caffeine 100mg tablets
special order - ergotamine tartrate; caffeine - oral tablet - 1mg ; 100mg
dihydroergotamine 1mg/1ml solution for injection ampoules
imported (canada) - dihydroergotamine mesilate - solution for injection - 1mg/1ml
dihydroergotamine mesylate injection
hikma farmaceutica - dihydroergotamine mesylate (unii: 81axn7r2qt) (dihydroergotamine - unii:436o5hm03c) -
dromelate- dihydroergotamine mesylate injection, solution
it3 medical llc - dihydroergotamine mesylate (unii: 81axn7r2qt) (dihydroergotamine - unii:436o5hm03c) - dihydroergotamine mesylate injection, usp is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. there have been a few reports of serious adverse events associated with the coadministration of dihydroergotamine and potent cyp 3a4 inhibitors, such as protease inhibitors and macrolide antibiotics, resulting in vasospasm that led to cerebral ischemia and/or ischemia of the extremities. the use of potent cyp 3a4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) with dihydroergotamine is, therefore contraindicated (see warnings: cyp 3a4 inhibitors) dihydroergotamine mesylate injection, usp should not be given to patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have clinical symptoms or findings consistent with coronary artery vasospasm including prinzmetal's variant angina. (see
medihaler ergotamine
inova pharmaceuticals (new zealand) limited - ergotamine tartrate 0.36mg - aerosol inhaler, metered dose - 0.36 mg/dose - active: ergotamine tartrate 0.36mg
trudhesa- dihydroergotamine mesylate spray, metered
impel pharmaceuticals inc. - dihydroergotamine mesylate (unii: 81axn7r2qt) (dihydroergotamine - unii:436o5hm03c) - trudhesa is indicated for the acute treatment of migraine with or without aura in adults. limitations of use trudhesa is not indicated for the preventive treatment of migraine. trudhesa is not indicated for the management of hemiplegic or basilar migraine. trudhesa is contraindicated in patients: - with concomitant use of strong cyp3a4 inhibitors, such as protease inhibitors (e.g., ritonavir, nelfinavir, or indinavir), macrolide antibiotics (e.g., erythromycin or clarithromycin), and antifungals (ketoconazole or itraconazole) [see warnings and precautions (5.1) and drug interactions (7.1)] - with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or patients who have clinical symptoms or findings consistent with coronary artery vasospasm, including prinzmetal's variant angina [see warnings and precautions (5.4)] - with uncontrolled hypertension [see warnings and precautions (5.5)] - with peripheral arterial disease - with sepsis - following vascular surge